Phillip Frost adds OPKO shares; indirect stake tops 214.9M
Rhea-AI Filing Summary
OPKO Health (OPK) CEO and Chairman Phillip Frost, M.D. reported multiple purchases of OPKO common stock on 11/18/2025. The transactions, coded as open-market or private purchases, ranged from $1.245 to $1.29 per share across several small trades.
Following these transactions, Frost is shown as beneficially owning 214,966,448 OPKO shares indirectly, as noted in a footnote describing Frost Gamma Investments Trust and related entities. Additional holdings of 3,568,951 shares are listed as directly owned, and 30,127,177 shares as indirectly owned through Frost Nevada Investments Trust, with both positions also accompanied by detailed ownership-disclaimer language. Frost is identified as a director, 10% owner, CEO and Chairman of OPKO Health.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 410 | $1.245 | $510.45 |
| Purchase | Common Stock | 49,590 | $1.25 | $62K |
| Purchase | Common Stock | 66,635 | $1.255 | $84K |
| Grant/Award | Common Stock | 46,700 | $1.26 | $59K |
| Purchase | Common Stock | 15,000 | $1.265 | $19K |
| Purchase | Common Stock | 1,772 | $1.27 | $2K |
| Purchase | Common Stock | 212,608 | $1.275 | $271K |
| Purchase | Common Stock | 69,728 | $1.28 | $89K |
| Purchase | Common Stock | 428 | $1.2847 | $549.85 |
| Purchase | Common Stock | 83,556 | $1.285 | $107K |
| Purchase | Common Stock | 1 | $1.2859 | $1.29 |
| Purchase | Common Stock | 33,572 | $1.29 | $43K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. These securities are held by Frost Nevada Investments Trust, of which the Reporting Person is the trustee and Frost-Nevada, L.P. is the sole and exclusive beneficiary. The Reporting Person is one of seven limited partners of Frost-Nevada, L.P. and the sole shareholder of Frost-Nevada Corporation, the sole general partner of Frost-Nevada, L.P. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
FAQ
What insider transaction did OPKO Health (OPK) report for 11/18/2025?
On 11/18/2025, OPKO Health reported that Phillip Frost, M.D. engaged in multiple purchases of common stock, with trades coded as purchases and prices ranging from $1.245 to $1.29 per share.
What is Phillip Frost’s relationship to OPKO Health (OPK)?
Phillip Frost, M.D. is identified as a director, a 10% owner, and an officer of OPKO Health, holding the titles of CEO & Chairman.
How are Phillip Frost’s indirect OPKO (OPK) holdings structured according to the filing?
Footnote 1 explains that 214,966,448 shares are held by Frost Gamma Investments Trust, with a chain of related entities in which Phillip Frost has interests. Footnote 2 explains that 30,127,177 shares are held by Frost Nevada Investments Trust through Frost-Nevada, L.P. In both cases, the reporting person states that beneficial ownership is disclaimed except to the extent of any pecuniary interest.
Does the OPKO (OPK) Form 4 include any ownership disclaimers by Phillip Frost?
Yes. Both Footnote 1 and Footnote 2 state that the reporting person disclaims beneficial ownership of the referenced securities, except to the extent of any pecuniary interest, and that the report shall not be deemed an admission of beneficial ownership for Section 16 or any other purpose.